Innate Pharma Management

Management criteria checks 3/4

Innate Pharma's CEO is Mondher Mahjoubi, appointed in Dec 2016, has a tenure of 6.75 years. total yearly compensation is €1.09M, comprised of 43.1% salary and 56.9% bonuses, including company stock and options. directly owns 0.64% of the company’s shares, worth €1.35M. The average tenure of the management team and the board of directors is 5.2 years and 4.8 years respectively.

Key information

Mondher Mahjoubi

Chief executive officer

€1.1m

Total compensation

CEO salary percentage	43.1%
CEO tenure	6.8yrs
CEO ownership	0.6%
Management average tenure	5.2yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mondher Mahjoubi's remuneration changed compared to Innate Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-€63m
Mar 31 2023	n/a	n/a	-€60m
Dec 31 2022	€1m	€470k	-€58m
Sep 30 2022	n/a	n/a	-€40m
Jun 30 2022	n/a	n/a	-€22m
Mar 31 2022	n/a	n/a	-€34m
Dec 31 2021	€1m	€470k	-€45m
Jun 30 2021	n/a	n/a	-€8m
Mar 31 2021	n/a	n/a	-€4m
Dec 31 2020	€1m	€470k	-€829k
Sep 30 2020	n/a	n/a	-€54m
Jun 30 2020	n/a	n/a	-€44m
Mar 31 2020	n/a	n/a	-€33m
Dec 31 2019	€1m	€470k	€8m
Sep 30 2019	n/a	n/a	€5m
Jun 30 2019	n/a	n/a	€31m
Mar 31 2019	n/a	n/a	€17m
Dec 31 2018	€1m	€470k	€3m
Sep 30 2018	n/a	n/a	-€19m
Jun 30 2018	n/a	n/a	-€40m
Mar 31 2018	n/a	n/a	-€44m
Dec 31 2017	€750k	€470k	-€48m
Sep 30 2017	n/a	n/a	-€28m
Jun 30 2017	n/a	n/a	-€8m
Mar 31 2017	n/a	n/a	€3m
Dec 31 2016	€2k	n/a	€13m

Compensation vs Market: Mondher's total compensation ($USD1.17M) is above average for companies of similar size in the German market ($USD603.52K).

Compensation vs Earnings: Mondher's compensation has been consistent with company performance over the past year.

CEO

Mondher Mahjoubi (65 yo)

6.8yrs

Tenure

€1,091,442

Compensation

Dr. Mondher Mahjoubi, M.D., serves as Chairman at PDC line Pharma SAS since June 2020. He has been the Chairman of Executive Board and Chief Executive Officer of Innate Pharma S.A. since December 30, 2016....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Herve Brailly	Co-Founder & Chairman of Supervisory Board	24.7yrs	€100.00k	0.92% € 1.9m
Mondher Mahjoubi	Chairman of Executive Board & CEO	6.8yrs	€1.09m	0.64% € 1.4m
Yannis Morel	Executive VP of Product Portfolio Strategy & Business Development and Member of Executive Board	8.3yrs	€511.78k	0.19% € 407.1k
François Romagné	Founder	no data	no data	no data
Eric Vivier	Founder	5.7yrs	no data	0.23% € 485.7k
Marc Bonneville	Founder	no data	no data	no data
Jean Fournié	Founder	no data	no data	no data
Alessandro Moretta	Founder	no data	no data	no data
Frederic Lombard	Senior VP & CFO	2.4yrs	no data	0.0012% € 2.5k
Odile Belzunce	Vice President of Compliance & Operations	4.7yrs	no data	0.050% € 106.1k
Henry Wheeler	Vice President of Investor Relations & Communication	less than a year	no data	0.0012% € 2.5k
Claire de Blanquat	VP of Legal & Corporate Affairs and Secretary of the Supervisory Board	less than a year	no data	0.0012% € 2.5k

5.2yrs

Average Tenure

54.5yo

Average Age

Experienced Management: IDDA's management team is seasoned and experienced (5.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Herve Brailly	Co-Founder & Chairman of Supervisory Board	6.8yrs	€100.00k	0.92% € 1.9m
Olivier Martinez	Member of Supervisory Board	no data	no data	no data
Ruslan Medzhitov	Strategic Advisory Board Member	4.8yrs	no data	no data
Gilles Brisson	Independent Member of Supervisory Board	16.2yrs	€30.00k	0.091% € 192.1k
Jean-Yves Blay	Independent Member of Supervisory Board	5.8yrs	€20.00k	0.000060% € 127.0
Irina Staatz-Granzer	Independent Vice Chairman of Supervisory Board	14.3yrs	€41.00k	0.031% € 66.0k
Pascale Boissel	Independent Member of Supervisory Board	3.3yrs	€53.67k	0.0012% € 2.6k
Miriam Merad	Chairman of Strategic Advisory Board	4.8yrs	no data	no data
Veronique Chabernaud	Independent Member of Supervisory Board	8.4yrs	€51.00k	0.000010% € 21.2
Sebastian Amigorena	Strategic Advisory Board Member	4.8yrs	no data	no data
Aurelien Marabelle	Strategic Advisory Board Member	4.8yrs	no data	no data
Tanguy Seiwert	Strategic Advisory Board Member	4.8yrs	no data	no data

4.8yrs

Average Tenure

62yo

Average Age

Experienced Board: IDDA's board of directors are considered experienced (4.8 years average tenure).

Innate Pharma Management

Management criteria checks 3/4

Key information

Recent management updates

Innate Pharma S.A., Annual General Meeting, May 22, 2025

Innate Pharma SA Announces Board Changes

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Executive Changes

Recent updates

Innate Pharma S.A., Annual General Meeting, May 22, 2025

Innate Pharma S.A. to Report First Half, 2025 Results on Sep 17, 2025

Innate Pharma SA Announces Board Changes

Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age